— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected.
— Revenues grew 62% to $94.6 million, vs. $88.4 million expected.
— Research and development expenses were $62.6 million, compared to $53.1 million last year.
— FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from the previous range of $320 million to $330 million.
— ACAD shares fell 0.81% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key highlights from Autodesk (ADSK) Q4 2021 earnings results
Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per
Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%
Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus
Virgin Galactic stock tanks on delayed test flight
Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000
